comprehensive -WSS

comprehensive

author：leisure time 2025-09-14 11:49:05 - browse：7481

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Stigma and the return of syphilis

WSS

Stigma and the return of syphilis

Vertigo drug brings hope for rare neuron disorder, Niemann

Time to name cancers by genetics, not organ of origin, expert says

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Report: NIH

Do more moles mean more problems? Not so, says new study

focus

comprehensive

focus

The high cost of giving birth even with insurance

Do more moles mean more problems? Not so, says new study

Cancer drug shortages should be causing more outrage

Insmed lung disease drug hits target in key Phase 3 trial

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A $475,000 price tag for a new cancer drug: crazy or meh?

In age of alternative facts, a scholarly course on calling out crap

FDA drug safety: Singulair case shows systemic surveillance flaws

Drug repurposing or repositioning? The language matters

Vertex non

entertainment

Quicker fix for pulse oximeters urged during FDA public meeting

Akili, maker of video game for ADHD, to be acquired for 34 million

Do more moles mean more problems? Not so, says new study

Medicare drug price negotiation’s day in court

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

First Opinion Podcast: What happens when kids become caregivers?

focus

explore

leisure time

entertainment